SLC27A2 and neoplasm: Tumour cell-derived granulocyte macrophage-colony stimulating factor (GM-CSF) activates MDSCs via inducing STAT3-mediated fatty acid transport protein 2 (FATP2), and pharmacological blockade of the latter via lipofermata reduced ROS expression, MDSC immunosuppressive activity, and tumour burden [87].